Evidence map›Paper›PMID 34537044›Full record

SynthesisBMC medical genomics2021

Ethnicity-stratified analysis of the association between XRCC3 Thr241Met polymorphism and leukemia: an updated meta-analysis.

Zhengjun Xie, Wei Peng, Qiuhua Li, Wei Cheng, Xin Zhao

Abstract readMeta-Analysis
In one paragraph

Synthesis in BMC medical genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhengjun XieDepartment of Hematology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhufeng Avenue 1439, Zhuhai, 519000, China. zhj_xie@hotmail.com.
Wei PengDepartment of Hematology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhufeng Avenue 1439, Zhuhai, 519000, China.
Qiuhua LiDepartment of Hematology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhufeng Avenue 1439, Zhuhai, 519000, China.
Wei ChengDepartment of Hematology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhufeng Avenue 1439, Zhuhai, 519000, China.
Xin ZhaoDepartment of Hematology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhufeng Avenue 1439, Zhuhai, 519000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPresently, whether X-ray repair cross complementing group 3 (XRCC3) Thr241Met polymorphism is correlated to leukemia risk remains controversial. Because of this reason, the objective of current study is to explore whether XRCC3 Thr241Met polymorphism confers risk to leukemia.

methodsTwo independent authors systematically and comprehensively searched Pubmed, Embase, the Cochrane library, Google academic, China National Knowledge Infrastructure (CNKI). Search time is from database foundation to March 2021.

resultsOverall, significant associations between leukemia risk and XRCC3 Thr241Met polymorphism were found in Caucasian population by allele contrast (T vs. C: OR 1.20, 95% CI 1.02-1.40), homozygote comparison (TT vs. CC: OR 1.35, 95% CI 1.05-1.73), and recessive genetic model (TT vs. TC/CC: OR 1.31, 95% CI 1.04-1.64).

conclusionsThe present meta-analysis suggests that the XRCC3 Thr241Met polymorphism may be a risk factor for leukemia in Caucasian population.

Indexed as

DNA-Binding ProteinsGenetic Predisposition to DiseaseLeukemiaHumansPolymorphism, Single NucleotideRisk FactorsWhite PeopleDNA-Binding ProteinsX-ray repair cross complementing protein 3Genetic polymorphismLeukemiaMeta-analysisXRCC3

Identifiers

PMID34537044
PMCPMC8449464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.